Table 7.

Comparison of neutralization activity of VRC01, GL-VRC01, and PG9 antibodies against JRFL E168K pseudoviruses with differentially glycosylated gp160 Env

IC₅₀ indicates antibody concentration required to inhibit pseudoviral activity by 50%; S.D. is standard deviation for the data from two independent experiments.

Pseudovirus Env	IC50 ±S.D. (μg/ml)
	VRC01	GL-VRC01	PG9
WT gp160	0.0061 ± 0.001	a	0.004 ± 0.001
ΔG11 gp160	0.00073 ± 0.001	2.95 ± 0.12	0.02 ± 0.003
ΔG13 gp160	0.00074 ± 0.001	0.19 ± 0.05	0.02 ± 0.003
ΔG15F gp160	0.0004 ± 0.001	0.64 ± 0.07	0.58 ± 0.5

^a There was no detectable neutralization until 10 μg/ml.